Early but not late allograft nephrectomy reduces allosensitization after transplant failure

Alp Sener, MD, FRCSC; Anand K. Khakhar, MD; Christopher Y. Nguan, MD, FRCSC; Andrew A. House, MD; Anthony M. Jevnikar, MD; Patrick P. Luke, MD, FRCSC


Abstract

Introduction: Allosensitization is a significant obstacle to retransplantation for patients with primary renal graft failure.

Methods: We assessed the impact of allograft nephrectomy (Group I) and weaning of immunosuppression (Group II) on percent panel reactive antibody (%PRA) at various time points after graft failure in 132 patients with a median follow-up of 47 months. Of these, 68% had allograft nephrectomy while 32% were placed on the waiting list and were either taken off immunosuppression, left on prednisone or on low-dose immunosuppressive therapy.

Results: When groups were stratified into early (<6 months) and late (>6 months) graft failure, patients who had transplant nephrectomy for early failure demonstrated a decline in %PRA from 46% at time of graft failure to 27% at last follow-up (p = 0.02); conversely, %PRA continued to rise in Group II experiencing early allograft failure. Both Groups I and II patients with late graft failure maintained elevated %PRA at last follow-up.

Conclusion: Allograft nephrectomy may play a role in limiting allosensitization in patients with early but not late graft failures.

Résumé

Introduction : L’allosensibilisation est un obstacle important à la retransplantation chez les patients présentant un échec primaire de la greffe rénale.

Méthodologie : Nous avons évalué l’impact d’une néphrectomie du greffon (groupe I) et du sevrage de l’immunosuppression (groupe II) sur le taux d’immunisation (%PRA) à différents points dans le temps après l’échec de la greffe chez 132 patients; le suivi médian était de 47 mois. Sur les 132 patients, 68% ont subi une néphrectomie du greffon, tandis que 32% ont été placés sur la liste d’attente, et on a soit mis fin à leur traitement d’immunosuppression, soit poursuivi leur traitement par prednisone ou par un agent immunosuppresseur à faible dose.

Résultats : Lorsque les groupes ont été stratifiés en fonction de l’échec précoce (< 6 mois) et tardif (> 6 mois) de la greffe, les patients qui ont subi une néphrectomie du greffon en raison d’un échec précoce ont montré une baisse du PRA, passant de 46 % au moment de l’échec de la greffe à 27 % lors du dernier suivi (p = 0.02); en revanche, le PRA a continué d’augmenter chez les patients du groupe II qui ont présenté un échec précoce de la greffe. Dans les deux groupes, les patients ayant présenté un échec tardif de la greffe présentaient toujours un PRA élevé lors du dernier suivi.

Conclusion : La néphrectomie du greffon peut contribuer à limiter l’allosensibilisation dans les cas d’échec précoce de la greffe, mais pas dans les cas d’échec tardif.

Introduction

The number of patients returning to dialysis due to poor renal allograft function is significant and represents over 10% of the total dialysis population each year. Unfortunately, allosensitization presents a considerable barrier to re-transplantation in these patients. Percent panel reactive antibody (%PRA), a surrogate marker of allosensitization, has been reported to rise significantly after a failed renal allograft, as the graft continues to be a source of antigenic stimulation for anti-human leukocyte antigen (HLA) antibodies. As a consequence, these highly sensitized recipients may be disadvantaged by prolonged waiting times, as well as inferior repeat allograft survival rates; these recipients often suffer from complications secondary to increased immunosuppressive requirements.

Considerable debate persists regarding the optimal management of patients with a failed renal allograft. However, it is widely accepted that not all failed allografts need removal. While early post-transplant allograft nephrectomy (AN) for vascular thromboses, infections and irreversible or accelerated rejections remain mandatory, the management of the chronically rejected kidney poses a challenge. Certain indications, such as prolonged fever, graft tenderness, hematuria, uncontrolled hypertension and recurrent infections, are accepted indications for AN in the chronically rejected graft, yet several centres continue to perform AN to also prevent allosensitization. Although previous studies, including our own, confirm that %PRA increases after renal transplantation and that AN does not appear to mitigate this sensitization, it is not known whether the timing of AN affects allosensitization. For patients who are not candidates for AN or for those with chronically rejected grafts, immunosuppression may be discontinued while they...
continue to wait for a second transplant. However, the effects of this widely accepted strategy on allosensitization are not well-documented.

The aim of this study is to determine the relationship between the timing of AN and the changes in %PRA. Additionally, we hypothesize that the management of immunosuppression in patients with failed allografts may affect the %PRA in patients placed on the waiting list for re-transplantation.

**Materials and methods**

Between May 1994 and June 2001, 132 patients were diagnosed with primary renal graft failure at our centre. All appropriate approvals from our Institutional Review Board were obtained prior to starting this analysis.

Overall, the mean patient age was 48 ± 12 years (90 males, 42 females). Median primary allograft survival was 5.2 years with a median patient follow-up of 2.9 years after graft failure. Of these patients, 90 had undergone AN (Group I, 64 males, 26 females), whereas the remaining 42 patients were placed on the transplant waiting list (Group II, 26 males, 16 females) under varying degrees of immunosuppression.

We evaluated various parameters, including patient demographics, cause of original end-stage renal disease, graft survival, %PRA levels before and at various intervals after transplant, reasons for AN and any associated complications. The PRA testing was carried out using a complement-dependent cytotoxicity assay (AHG-enhanced in the case of T cells). No patients received blood transfusions while in hospital, however, we could not ascertain whether any transfusions were given at satellite dialysis centres. All patients undergoing AN had their immunosuppression terminated after the procedure. Patients who did not receive AN remained on 1 of 3 protocols of immunosuppression: (1) no wean (maintained on low-dose calcineurin inhibitor and prednisone); (2) partial wean (maintained on low-dose prednisone); and (3) total wean (withdrawn from immunosuppression at time of graft loss). Subgroup analysis was carried out to determine if the timing of AN resulted in a change in overall %PRA within subgroups.

Statistics were carried out using Students t-test (SPSS 11.0, Chicago, IL). All data are reported as mean ± standard deviation. Statistical significance was accepted at the 95% confidence interval.

**Results**

There was no significant age difference between patients in Group I and II (45 ± 12 years, 48 ± 11 years, respectively) and there were more males in Group I (71% vs. 26%, p = 0.03) (Table 1). The etiologies of renal dysfunction were similar between the 2 groups and were congruent with previous reports. Although graft survival was not statistically significant between the 2 groups (Group I: 5.4 ± 5.7 years vs. Group II: 6.8 ± 4.3 years, p = 0.15), the time to the last follow-up after the AN in Group I or graft failure in Group II was greater in the latter cohort (35 ± 32 months vs. 60 ± 50 months, p = 0.14). Of the 90 patients who received AN, 21% were due to technical failure, 20% to acute onset rejection and hemorrhage, 2% to hyperacute rejection, 3% due to primary non-function, 19% to permit weaning of

<table>
<thead>
<tr>
<th>Category</th>
<th>Group I</th>
<th>Group II</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>45 ± 12</td>
<td>48 ± 11</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>64 (71)</td>
<td>26 (62)</td>
<td>0.03</td>
</tr>
<tr>
<td>Female</td>
<td>26 (29)</td>
<td>16 (38)</td>
<td>0.03</td>
</tr>
<tr>
<td>Cause of ESRD (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTN</td>
<td>22 (24)</td>
<td>9 (21)</td>
<td>NS</td>
</tr>
<tr>
<td>DM</td>
<td>19 (21)</td>
<td>8 (19)</td>
<td>NS</td>
</tr>
<tr>
<td>GN</td>
<td>20 (22)</td>
<td>9 (21)</td>
<td>NS</td>
</tr>
<tr>
<td>VUR</td>
<td>12 (13)</td>
<td>7 (17)</td>
<td>NS</td>
</tr>
<tr>
<td>PCKD</td>
<td>3 (3)</td>
<td>2 (4)</td>
<td>NS</td>
</tr>
<tr>
<td>SLE</td>
<td>1 (1)</td>
<td>1 (2)</td>
<td>NS</td>
</tr>
<tr>
<td>Other</td>
<td>13 (14)</td>
<td>6 (14)</td>
<td>NS</td>
</tr>
<tr>
<td>Graft survival (years)</td>
<td>5.4 ± 5.7</td>
<td>6.8 ± 4.3</td>
<td>NS</td>
</tr>
<tr>
<td>Follow-up (months)</td>
<td>35 ± 32</td>
<td>60 ± 50</td>
<td>0.14</td>
</tr>
<tr>
<td>Reason for AN (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical failure</td>
<td>19 (21)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Acute rejection</td>
<td>18 (20)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Hyperacute rejection</td>
<td>2 (2)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Primary non-function</td>
<td>3 (3)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chronic allograft nephropathy</td>
<td>17 (19)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Infection</td>
<td>10 (12)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>21 (23)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>AN (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early (&lt;6 months)</td>
<td>39 (43)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Late (&gt;6 months)</td>
<td>51 (57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>77 (86)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Minor</td>
<td>9 (10)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Major</td>
<td>4 (4)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Immunosuppression wean protocol (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No wean</td>
<td>7 (17)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Partial wean</td>
<td>21 (50)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total wean</td>
<td>90 (100)</td>
<td>14 (33)</td>
<td>–</td>
</tr>
</tbody>
</table>

ESRD: End-stage renal disease; HTN: hypertension; DM: diabetes mellitus; GN: glomerulonephritis; VUR: vesicoureteric reflux; PCKD: polycystic kidney disease; SLE: systemic lupus erythematosus; AN: allograft nephrectomy; NS: not significant.
immunosuppression, 12% to chronic or recurrent infections and 23% to other non-specific causes (Table 1). Significant complications related to AN included 9 minor complications (postoperative hemorrhage [n = 1]; cerebrovascular accident [n = 1]; incisional hernia [n = 2]; wound infection [n = 3]; deep vein thromboses [n = 1]; infectious colitis [n = 1]) and 4 major complications which led to perioperative death (hemorrhage [n = 1]; cerebrovascular accidents [n = 2]; pulmonary embolism [n = 1]).

All patients in Group 1 were completely weaned off their immunosuppression, whereas in Group II, 17% (n = 7), 50% (n = 21) and 33% (n = 33) of patients received no weaning, partial weaning or total weaning of their maintenance immunosuppression (Table 1). Decisions for the type of weaning therapy were based on timing of the graft failure, residual renal function at the time of graft failure and physician preference.

Patients in Group I had %PRA levels increase from a baseline of 9.1 ± 15.3% pre-transplantation to 34.2 ± 30.4% at the time of AN; levels continued to increase up to 6 months after the procedure to 45.0 ± 38.1% and then declined by the time of last follow-up to 33.8 ± 30.4% (p = 0.01 vs. the levels at 6 months). Although a similar rise in %PRA was observed following transplantation in Group II patients (pre-transplant: 9.2 ± 18.6% vs. last follow-up: 35.4 ± 35.2%, p = 0.001), these patients did not exhibit a peak %PRA at 6 months after graft failure, as seen in Group I, but demonstrated a gradual rise in %PRA.

In the subgroup analysis, we found that in the 39 Group I patients who underwent early AN (<6 months following transplantation), %PRA levels declined within the first 6 months after AN and decreased until the time of last follow-up (pre-transplant: 7.7 ± 15.2%; time of AN: 46.2 ± 29.7% and last follow-up: 26.8 ± 28.9%, p = 0.02 vs. time of AN) (Fig. 1). In comparison, the subgroup of 6 Group II patients who also had early graft failure (<6 months following transplantation) and were maintained on maintenance immunosuppression showed a gradual increase in %PRA from baseline of 36.2 ± 36.8% (pre-transplant) to 82.8 ± 29.4% at the time of last follow-up (p = 0.02) (Fig. 1). At the time of last follow-up, %PRA levels were significantly lower between patients who received AN for early graft failure versus those who were maintained on immunosuppression (p < 0.03). Interestingly, 5 people in Group II were totally weaned off their immunosuppression and only 1 was left on partial immunotherapy.

In comparison, 51 of the Group I patients who underwent late AN (>6 months after transplantation) revealed that %PRA continued to rise from pre-transplant values of 9.0 ± 11.1% to 34.2 ± 30.4% at the time of nephrectomy and to 41.9 ± 30.1% at the time of last follow-up (p = 0.002) (Fig. 2). Group II patients who developed late graft failure (>6 months after transplantation) followed a similar rising trend in %PRA levels from 4.8 ± 9.0% at baseline to 17.7 ± 26.2% at time of graft failure and to 27.7 ± 29.4% at the time of last follow-up (p = 0.02) (Fig. 2). Within this cohort of Group II patients (n = 36), 9 underwent total weaning, 18 had partial weaning and 8 had no weaning of immunosuppression.

Fig. 3 demonstrates the change in %PRA in Group II patients who were placed on various immunosuppressive regimens following graft failure. Although not statistically significant, patients who were completely weaned off immunosuppression had greater elevations in the %PRA (increase of 15%) at the time of last follow-up compared with patients who had their immunotherapy partially weaned (increase of

---

**Table 2. Overall %PRA profiles following renal transplantation in Group I (allograft nephrectomy) and Group II (wean protocol without allograft nephrectomy) patients**

<table>
<thead>
<tr>
<th></th>
<th>Pre-transplant</th>
<th>Time of graft failure/ allograft nephrectomy</th>
<th>6 months after graft failure</th>
<th>Last follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (%)</td>
<td>9.1 ± 15.3</td>
<td>34.2 ± 30.4*</td>
<td>45.5 ± 38.1*</td>
<td>33.8 ± 30.4*</td>
</tr>
<tr>
<td>Group II (%)</td>
<td>9.2 ± 18.6</td>
<td>24.4 ± 32.3*</td>
<td>24.4 ± 31.6*†</td>
<td>35.4 ± 35.2*</td>
</tr>
</tbody>
</table>

Values are mean ± standard deviation, *p < 0.05 vs. pre-transplant and †p < 0.05 vs. Group I. PRA: panel reactive antibody.
Re-transplantation occurs in up to 25% of patients requiring renal replacement therapy. This paper highlights the importance of minimizing the extent of allosensitization in renal transplant patients to not only maximize the lifespan of the allograft, but also to abrogate the potentially detrimental immunological effects of a failed graft on re-transplantability.

It has been argued that a failed renal transplant is a continuous source of antigenic stimulation for anti-HLA antibodies and thus may decrease the possibility of finding a crossmatch-negative second kidney. Apart from this immunological effect, a failed allograft left in situ may also induce a chronic inflammatory response leading to erythropoietin resistance, hypoalbuminemia and infection. On the contrary, others have argued that the removal of a non-functional allograft is followed by a rise in HLA-antibodies, suggesting that the graft may be acting as an “immunological sponge” to absorb low levels of allo-antibodies or may regulate the capacity of the recipient’s immune system to mount a response to the donor’s major histocompatibility complex (MHC) antigens through the activation of regulatory T cells. In addition, the failing graft may provide some residual diuresis and solute clearance which may assist in fluid balance during dialysis.

Lair and colleagues showed, in an experimental murine cardiac transplant model and in a large cohort of human kidney transplant patients, that the presence of the first rejected graft did not influence the survival of the second transplant. In addition, these authors found a higher incidence of anti-HLA antibodies and a higher %PRA in re-transplant patients who underwent primary AN. More recently, Ahmad and colleagues similarly showed that nephrectomy of a failed graft did not influence the survival of a second transplant when compared to patients with retained failed allografts who also received second transplants. Using multivariate analysis, however, it was found that the only predictor of patient and graft survival was %PRA prior to the second transplant. Both these contemporary studies confirm older reports by Sumrani and colleagues who showed that patients undergoing AN prior to re-transplantation had a higher %PRA and thus a higher incidence of delayed graft function in subsequent transplants. Importantly, rates of acute rejection and long-term graft outcomes were similar between patients who had undergone AN and those who retained their grafts. These studies spanning several decades concur with our data that %PRA does increase following AN for late graft losses (>6 months following transplantation). Not surprisingly, we also demonstrate that %PRA continued to rise even if the failed graft was left in situ, albeit to a lesser degree.

Our study is the first to confirm that the time of allograft failure and subsequent AN may influence long-term allosensitization. This phenomenon is clinically important in managing patients with early graft failure. Similar to previous studies mentioned above, we reaffirm that the common practice to perform AN in patients experiencing graft failure within 6 months of transplantation should be continued to minimize further sensitization and to maximize the possibility of future retransplantation. Conversely, we were unable
to demonstrate that AN has a beneficial effect against allo-
sensitization in late graft failure. Donor-specific PRA fol-
lowing an AN was not evaluated in any of our patients, but
should be carried out in future trials.

Although AN is technically straightforward, the poten-
tial for significant morbidity should be considered given
the inherent comorbidities observed in most renal failure
patients. Compared with previous authors reporting morbidi-
ity rates of up to 20% and 39%, respectively,1,2,3 our study
demonstrated 10% morbidity and 4% mortality rates.

Subgroup analysis showed that in the small group of
patients who did not receive AN for early graft failure, %PRA
rose significantly throughout the period of follow-up. An
explanation for these findings likely resides in their higher
%PRA prior to transplantation compounded with either pri-
mary non-function (n = 2) and steroid-resistant rejection
(n = 4). Although antibody-mediated rejection may have
also contributed to the rapid graft loss, neither donor-specific
antibody testing nor histopathologic stains were available
during the time of this study to confirm this speculation. In
addition, almost all of these patients had complete immu-
nosuppression withdrawal at the time of graft failure, which
may have played a significant contribution to further allo-
sensitization in these already sensitized individuals. Further
studies using a larger cohort of patients will be better apt at
discerning the immunological outcomes in patients undergo-
ing early graft failure.

The debate continues over how much and how long
immunosuppression should be maintained following
allograft loss. Strategies include early discontinuation of
immunosuppression to prolonged or gradual tapering of
medication or continuation of low-dose maintenance ther-
apy to minimize rejection and maintain diuresis.22-26 More
recently, Morales and colleagues showed that in patients
who developed late allograft failure (mean 44 months after
transplant), the immediate withdrawal of mycophenolate
mofetil followed by progressive withdrawal of calcineurin
inhibitors and prednisone over 3 months was successful in
62% of patients, whereas the remaining 38% of patients
still developed episodes of acute rejection requiring pulse
steroids (50%), coil embolization of the graft (48%) and
AN (2%).8 Interestingly, 46% of those patients who were
successfully weaned off immunosuppression developed sig-
ificant increases in their %PRA which complicated their
sensitization in these already sensitized individuals. Further
studies using a larger cohort of patients will be better apt at
discerning the immunological outcomes in patients undergo-
ging late graft failure.

6. Spieser DE, Jeannet M. Renal transplantation to sensitized patients: decreased graft survival probability
7. Ahmad N, Ahmad K, Rameode N. Does nephrectomy of failed allograft influence graft survival after
10. Khakhar AK, Shukhan VB, House AA, et al. The impact of allograft nephrectomy on percent panel reactive

that the patients in all 3 protocols had similarly low-starting
%PRAs, the greater increase in the latter group suggests that
the in situ graft may be a source of antigenic stimulation for
anti-donor HLA antibodies to form. Due to small overall
numbers, these changes in %PRA were not shown to be
statistically significant. Nevertheless, although the current
study was not powered enough to make a formal conclu-
sion, we highlight a potential trend which requires further
investigation.

Conclusion

Overall, although this study is retrospective in nature, the
data are the first to suggest that the time of graft failure and
subsequent AN may play a significant role in allosensitiza-
tion. Specifically, AN in patients experiencing graft failure
within 6 months of transplantation may assist in minimizing
further sensitization and maximizing the possibility of future
re-transplantation. Conversely, we were unable to demon-
strate that AN has a beneficial effect against allosensitization
in late graft failure. In addition, the potential role of immu-
nosuppressive therapy in modulating allosensitization in the
post-graft failure period cannot be discounted and requires
further investigation.

Competing interests: None declared.

This paper has been peer-reviewed.


Correspondence: Dr. Patrick P. Luke, London Health Sciences Centre, University Campus, 339 Windermere Rd, London, ON N6A 5A5; fax: 519-663-3858; patrick.luke@lhsc.on.ca